Medical Gases: CGMP, Certification and Reporting
Oxygen, nitrogen and the other medical gases are drugs, but for decades they were made under drug CGMP rules written for tablets and injectables. From 18 December 2025 they have their own: 21 CFR Part 213 sets CGMP for medical gases, and Part 211 now excludes them. Part 230, published in the same rule, sets how a designated medical gas is certified for market and what its holder must report afterwards. For a gas manufacturer, filler or transfiller the change is less about new obligations than about rebasing a quality system on the right part and closing the gaps the new text names.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
Why Medical Gases Have Their Own Part
Part 213 contains "the minimum current good manufacturing practice for preparation of medical gases for administration to humans or animals" (213.1). At the same time Part 211 was amended so that its scope excludes "positron emission tomography drugs and medical gases as defined in § 213.3(b)(12)" (211.1(a)).
The rule explains why some drug CGMP provisions do not carry over. It leaves out time limitations on production "because medical gases are generally not expected to expire or degrade", and it treats equipment cleaning differently "because these gases are generally manufactured in a sealed, closed system, and because cleaning at inappropriate times can introduce contaminants" (89 FR 51738, executive summary).
What Part 213 Requires
The structure follows Part 211: a quality unit with authority to approve or reject components, containers, labelling and gases and to review production records (213.22); written cleaning and maintenance procedures (213.67); calibration of automatic equipment and validation of computerised systems, with change control and data backup (213.68); and laboratory determination of conformance to final specifications, including identity and strength, before each batch is released (213.165).
Some provisions are written for gases specifically. On receipt of an incoming designated medical gas, the firm either performs full compendial testing or verifies a signed certificate of analysis carrying the supplier, gas, lot, actual results, methods, application number and signature, and an identity test is performed either way (213.82). Containers and closures must not alter the gas, and portable cryogenic containers need gas-specific use outlet connections that cannot readily be removed except by the manufacturer (213.94).
Certification of Designated Medical Gases
A designated medical gas is one defined in section 575(1) of the FD&C Act, manufactured or stored as a liquefied, nonliquefied or cryogenic gas and administered as a gas (213.3(b)(5)). Anyone seeking to introduce one into interstate commerce for the indications in section 576 files a request for certification under Part 230 (230.50).
Unless FDA denies it and notifies the applicant within 60 calendar days of filing, the certification is deemed granted and the gas is treated as having an approved application (230.105). Changes to the information in a granted certification, such as a new manufacturing facility, go in a supplement no later than 30 calendar days after the change (230.70), and an annual report is due within 60 calendar days of each new calendar year (230.80).
Postmarketing Reporting
Part 230 adds safety and quality reporting written for designated medical gases. A field alert report goes to the responsible FDA district office no later than 45 calendar days after the applicant obtains information suggesting a reportable incident, or no later than 3 working days where a rapid response to a public health risk may be needed, marked "Designated Medical Gas—Field Alert Report" (230.205).
Individual case safety reports for adverse events in humans are due as soon as possible and no later than 15 calendar days from meeting the reporting criteria with a minimum data set (230.220). Applicants and nonapplicants must promptly review safety information from any source, including the literature and other regulators (230.210).
Where Firms Fall Short
The common gap after a change like this is documentary: procedures, quality agreements and batch records that still cite Part 211, and procedures written for operations a gas plant does not have. Rebasing them section by section on Part 213 is the first piece of work, not the last.
The second is receipt. Transfillers that rely on certificates of analysis need the supplier-reliability programme §213.82(a)(2) requires and an identity test on every receipt; a certificate on file without either is not the control the regulation describes.
FREQUENTLY ASKED
When did Part 213 take effect?
On 18 December 2025. The final rule was published on 18 June 2024 (89 FR 51738); amendments to 21 CFR 4.2–4.4 in the same rule took effect on 2 February 2026.
Does Part 211 still apply to medical gases?
No. Section 211.1(a) now excludes medical gases as defined in 213.3(b)(12); their CGMP is in Part 213.
Can a transfiller rely on the supplier’s certificate of analysis?
Yes, if the certificate carries the content §213.82(a)(1) lists and the firm runs a programme to establish the supplier’s reliability. An identity test on receipt is required in either case (213.82(b)).
How quickly must a field alert report be filed?
No later than 45 calendar days from obtaining information suggesting a reportable incident, or no later than 3 working days where a rapid response to a public health risk may be needed (230.205).
The inspection-readiness playbook for this topic
PUT THIS PLAYBOOK TO WORK
- HOW-TO GUIDEHow to Rebase Medical Gas CGMP on Part 213 →Move a medical gas operation’s procedures from Part 211 to Part 213 and close the gaps the new part names.
- TEMPLATEMedical Gas Part 213 Gap Assessment →
A free account keeps what you save, remembers where you are across devices, and can send you the weekly regulatory briefing. Create a free account